Medication persistence and the use of generic and brand-name blood pressure-lowering agents

Journal of Hypertension

Volumn 32, Issue 5, 2014, Pages 1146-1153

  Corrao, Giovanni ^a   Soranna, Davide ^a   La Vecchia, Carlo ^b,c,d   Catapano, Alberico ^c,e   Agabiti Rosei, Enrico ^f   Gensini, Gianfranco ^g   Merlino, Luca ^h   Mancia, Giuseppe ^a,i  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^e Department of Pharmacological Sciences ^*  (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Operative Unit of Territorial Health Services   (Italy)

ⁱ ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

antihypertensive treatment; brand name; databases; discontinuation; generic

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAND NAME DRUG; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG; GENERIC DRUG; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG COST; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; ITALY; MAJOR CLINICAL STUDY; MALE; MIGRATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT WITHDRAWAL; COHORT ANALYSIS;

ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DRUGS, GENERIC; HUMANS; HYPERTENSION; ITALY; PATIENT COMPLIANCE;

EID: 84898457682     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000130     Document Type: Article

References (29)

1. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000; 51:149-162.
2. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005; 142:891-897.
3. Hakonsen H, Horn AM, Toverud EL. Price control as a strategy for pharmaceutical cost containment: what has been achieved in Norway in the period 1994-2004? Health Policy 2009; 90:277-285.
4. Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 1999; 15:519-533.
5. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008; 1:497-503.
6. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf 2001; 10:295-300.
7. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). EMA/837805/2011. 27 September 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2009/12/ WC500020062.pdf. [Accessed 22 April 2013].
8. Himmel W, Simmenroth-Nayda A, Neibling W, Ledig T, Jensen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005; 43:472-479.
9. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012; 23:213-221.
10. Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM. Effect of generic only drug benefits on seniors' medication use and financial burden. Am J Manag Care 2006; 12:525-532.
11. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood) (Suppl Web Exclusives):2004;W4-455-W4-468.
12. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166:332-337.
13. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and the use of generic drug therapies. Am J Manag Care 2009; 15:450-456.
14. Corrao G, Cesana G, Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008; 2:117-125.
15. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158:915-920.
16. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Melino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824.
17. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101-2107.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-619.
19. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons; 1995.
20. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51:228-235.
21. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25:1768-1797.
22. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40:794-811.
23. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
24. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of hypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24:1193-1200.
25. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20:72-80.
26. Vrijens B, Vincze G, Kristanto P, Urguhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
27. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. New York: John Wiley & Sons; 2000. pp. 219-222.
28. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Criceli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584-1590.
29. Nordmann S, Biard L, Ravaud P, Esposito-Farése M, Tubach F. Caseonly designs in pharmacoepidemiology: a systematic review. PLoS One 2012; 7:e49444.